The PD-L1 Biomarker Testing Market offers opportunities driven by the rising incidence of non-small cell lung cancer and the expanding use of immune checkpoint inhibitors. Growth is buoyed by AI ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...
FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results